ArticleIndian journal of endocrinology and metabolism
Cinacalcet and Parathyroidectomy Outcomes in Symptomatic and Asymptomatic Primary Hyperparathyroidism: A Retrospective Observational Study.
Article in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Primary hyperparathyroidism (PHPT) is a common and symptomatic endocrine disorder in India. There has been a notable rise in asymptomatic PHPT (urban India), creating a dilemma in optimal treatment approach-surgery or medical management. Cinacalcet is a calcimimetic used in managing PHPT, but data regarding its use from India is limited. This retrospective study aimed to assess the prevalence of asymptomatic PHPT, compare symptomatic versus asymptomatic PHPT and evaluate the real-world outcomes among patients managed with parathyroidectomy (PTX) or cinacalcet. Methods: A retrospective analysis was conducted on 90 PHPT patients seen between January 2020 and July 2024 at a tertiary care centre in New Delhi, India. Clinical, biochemical and imaging data were collected, and real-world outcomes were assessed for PTX and cinacalcet. Statistical analysis was performed using SPSS. Results: Of the 90 patients, 64.4% were symptomatic and 35.6% were asymptomatic. Symptomatic patients had higher parathyroid hormone (PTH) levels and more frequent MIBI localization. PTX was curative and led to significantly greater reductions in calcium ( Conclusion: A significant proportion of cases were asymptomatic PHPT, with biochemical and radiological profiles closely resembling those of symptomatic cases. While PTX provided definitive cure, cinacalcet led to short-term normalization of calcium and reduction of PTH. Cinacalcet serves as an alternative for patients who refuse surgery, are not candidates for surgery, or prefer medical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.